The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Por Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Publicado no Mult Scler (2017)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

Por Miller, Aaron E, O’Connor, Paul, Wolinsky, Jerry S, Confavreux, Christian, Kappos, Ludwig, Olsson, Tomas P, Truffinet, Philippe, Wang, Lin, D’Castro, Laura, Comi, Giancarlo, Freedman, Mark S
Publicado em 2012

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

Por Miller, Aaron E., Macdonell, Richard, Comi, Giancarlo, Freedman, Mark S., Kappos, Ludwig, Mäurer, Mathias, Olsson, Tomas P., Wolinsky, Jerry S., Bozzi, Sylvie, Dive-Pouletty, Catherine, O’Connor, Paul W.
Publicado em 2014

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use

Por O’Connor, Paul W., Lublin, Fred D., Wolinsky, Jerry S., Confavreux, Christian, Comi, Giancarlo, Freedman, Mark S., Olsson, Tomas P., Miller, Aaron E., Dive-Pouletty, Catherine, Bégo-Le-Bagousse, Gaëlle, Kappos, Ludwig
Publicado em 2013